Une nouvelle cellule dendritique impliquée dans l’immunité anti-tumorale

Nathalie Chaput; Julien Taieb; Evelyn Ullrich; Laurence Zitvogel

doi:10.1051/medsci/20062267567

Accueil

Tous les numéros

Volume 22 / Numéro 6-7 (Juin-Juillet 2006)

Med Sci (Paris), 22 6-7 (2006) 567-568

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 22, Numéro 6-7, Juin-Juillet 2006


Page(s)		567 - 568
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20062267567
Publié en ligne		15 juin 2006

Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1 : 41–9. [Google Scholar]
Steinman RM. Some interfaces of dendritic cell biology. Apmis 2003; 111 : 675–97. [Google Scholar]
Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95 : 7556–61. [Google Scholar]
Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410 : 1107–11. [Google Scholar]
Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12 : 214–9. [Google Scholar]
Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12 : 207–13. [Google Scholar]
Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114 : 379–88. [Google Scholar]
Smyth MJ, Takeda K, Hayakawa Y, et al. Nature’s TRAIL : on a path to cancer immunotherapy. Immunity 2003; 18 : 1–6. [Google Scholar]
Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and itsreceptors as targets for cancer therapy. Cancer Sci 2004; 95 : 777–83. [Google Scholar]
Shortman K, Villadangos JA. Is it a DC, is it an NK ? No, it’s an IKDC. Nat Med 2006; 12 : 167–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1 : 41–9. [Google Scholar]

[2] Steinman RM. Some interfaces of dendritic cell biology. Apmis 2003; 111 : 675–97. [Google Scholar]

[3] Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95 : 7556–61. [Google Scholar]

[4] Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410 : 1107–11. [Google Scholar]

[5] Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12 : 214–9. [Google Scholar]

[6] Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12 : 207–13. [Google Scholar]

[7] Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114 : 379–88. [Google Scholar]

[8] Smyth MJ, Takeda K, Hayakawa Y, et al. Nature’s TRAIL : on a path to cancer immunotherapy. Immunity 2003; 18 : 1–6. [Google Scholar]

[9] Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and itsreceptors as targets for cancer therapy. Cancer Sci 2004; 95 : 777–83. [Google Scholar]

[10] Shortman K, Villadangos JA. Is it a DC, is it an NK ? No, it’s an IKDC. Nat Med 2006; 12 : 167–8. [Google Scholar]